Alzheimer's Drugs Pipeline Therapeutics Review H1 2017 report covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 23, 40, 62, 1, 251, 90 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 109 and 46 molecules, respectively.
Alzheimer's Drugs Pipeline Review H1 2017 provides an overview of the Alzheimer's disease (Central Nervous System) pipeline landscape. Report provides comprehensive information on the therapeutics under development for Alzheimer's disease Pipeline (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Inquire for Complete 1181 pages report@ www.reportsnreports.com/contacts/i….aspx?name=928816 .
Companies Analysed In Report: AB Science SA, AbbVie Inc, AC Immune SA, Acadia Pharmaceuticals Inc, Accera Inc, Acelot Inc, Actinogen Medical Ltd, Acumen Pharmaceuticals Inc, Addex Therapeutics Ltd, Affibody AB, AFFiRiS AG, Alector LLC, Allergan Plc, Allinky Biopharma, ALSP Inc, Alzhyme Pty Ltd, Alzinova AB, AlzProtect SAS, Amarantus Bioscience Holdings Inc, Amgen Inc, Anavex Life Sciences Corp, Annexon Inc, Aphios Corp, Apodemus AB, Applied Research using OMIC Sciences SL, Aptevo Therapeutics Inc, Araclon Biotech SL, Archer Pharmaceuticals Inc, ArmaGen Inc, Artery Therapeutics Inc, Asceneuron SA, AskAt Inc, Astellas Pharma Inc, AstraZeneca Plc, Asubio Pharma Co Ltd, Avineuro Pharmaceuticals Inc, Axon Neuroscience SE, Axovant Sciences Ltd., Axxam SpA, Beactica AB, Berg LLC, BioArtic AB, Bioasis Technologies Inc, Biogen Inc, BioHealthonomics Inc, Biomar Microbial Technologies, Boehringer Ingelheim GmbH, Boryung Pharmaceutical Co Ltd, Bristol-Myers Squibb Company, Bsim2, Cantabio Pharmaceuticals Inc, Cardax Inc, Carna Biosciences Inc, Celon Pharma SA, CHA Bio & Diostech Co Ltd, Clera Inc, Cognition Therapeutics Inc, Cognosci Inc, CohBar Inc, Connexios Life Sciences Pvt Ltd, ContraVir Pharmaceuticals Inc, Corium International Inc, Coronis NeuroSciences Ltd, Cortice Biosciences Inc, Critical Outcome Technologies Inc, Crossbeta Biosciences BV, Daewoong Pharmaceutical Co Ltd, Daiichi Sankyo Company Ltd, Daval International Ltd, Denali Therapeutics Inc, DermaXon LLC, Domain Therapeutics SA, Dongkook Pharmaceutical Co Ltd, Eisai Co Ltd, Eli Lilly and Company, EncephRx Inc, Endece LLC, ENKAM Pharmaceuticals A/S, Ensemble Therapeutics Corp, Ensol Biosciences Inc, Epigen Biosciences Inc, Evotec AG, F. Hoffmann-La Roche Ltd, Genentech Inc, Genervon Biopharmaceuticals LLC, Genzyme Corp, GlaxoSmithKline Plc, GliaCure Inc, Glialogix Inc, Golden Biotechnology Corp, Grifols SA, H.
Lundbeck A/S, Heptares Therapeutics Ltd, HitGen LTD, HSRx Group, ICB International Inc, Ichor Medical Systems Inc, Icure Pharmaceutical Inc, Immungenetics AG, Impel NeuroPharma Inc, ImStar Therapeutics Inc, Inovio Pharmaceuticals Inc, IntelGenx Corp, Intellect Neurosciences Inc, Intra-Cellular Therapies Inc, INVENT Pharmaceuticals Inc, Io Therapeutics Inc, Ironwood Pharmaceuticals Inc, Jeil Pharmaceutical Co Ltd, Jiangsu Kanion Pharmaceutical Co Ltd, Johnson & Johnson, K-Stemcell Co Ltd, Kadmon Corp LLC, Kalgene Pharmaceuticals Inc, Kareus Therapeutics SA, Karuna Pharmaceuticals Inc, KineMed Inc, Krenitsky Pharmaceuticals Inc, Kyowa Hakko Kirin Co Ltd, Lead Discovery Center GmbH, Les Laboratoires Servier SAS, Lipopharma Therapeutics SL, Living Cell Technologies Ltd, Lupin Ltd, M3 Biotechnology Inc, ManRos Therapeutics, MedDay SA, Medestea Research & Production SpA, MedImmune LLC, Medisyn Technologies Inc, MEDRx Co Ltd, MEI Pharma Inc, MeiraGTx Ltd, Merck & Co Inc, Metabolic Solutions Development Company LLC, Microlin Bio Inc, Mithridion Inc, Mitochon Pharmaceuticals Inc, Mitsubishi Tanabe Pharma Corp, ModGene Pharma LLC, NAL Pharmaceuticals Ltd, Nanomerics Ltd, Nanotherapeutics Inc, Neuralstem Inc, Neuraltus Pharmaceuticals Inc, Neurim Pharmaceuticals Ltd, Neuro-Sys SAS, NeuroGenetic Pharmaceuticals Inc, NeuroNascent Inc, NeurOp Inc, Neuropore Therapies Inc, Neurotez Inc, New World Laboratories Inc, nLife Therapeutics SL, NLS Pharma Group, Novartis AG, NsGene A/S, Oligomerix inc, Orphit SAS, Oryzon Genomics SA, P2D Bioscience, Pain Therapeutics Inc, Palumed SA, Panacea Pharmaceuticals Inc, Peptron Inc, Pfizer Inc, PharmaKure Ltd, PharmatrophiX Inc, Pharmaxis Ltd, Pharnext SA, Prevacus Inc, Probiodrug AG, Proclara Biosciences Inc, Progenra Inc, ProMIS Neurosciences Inc, ProQR Therapeutics NV, Proteome Sciences Plc, Proteostasis Therapeutics Inc, QR Pharma Inc, Quimatryx SL, Radius Health Inc, Regenera Pharma Ltd, reMYND NV, Resverlogix Corp, Retrotope Inc, ReXceptor Inc, Rodos BioTarget GmbH, Sage Therapeutics Inc, Samjin Pharmaceutical Co Ltd, Samumed LLC, SanBio Inc, Saneron CCEL Therapeutics Inc, Sanofi, SBI Pharmaceuticals Co Ltd, Selvita SA, SeneXta Therapeutics SA, Serometrix LLC, Signum Biosciences Inc, Simcere Pharmaceutical Group, SK Biopharmaceuticals Co Ltd, SOM Biotech SL, Spectrum Pharmaceuticals Inc, Spherium Biomed SL, Stemedica Cell Technologies Inc, Sumitomo Dainippon Pharma Co Ltd, Summit Therapeutics Plc, Suven Life Sciences Ltd, T3D Therapeutics Inc, Takeda Pharmaceutical Company Ltd, TauRx Therapeutics Ltd, TechnoPhage SA, Teijin Pharma Ltd, Teikoku Pharma USA Inc, Telocyte LLC, Tetra Discovery Partners LLC, Thera Neuropharma Inc, Theranexus SAS, Therapix Biosciences Ltd, Toyama Chemical Co Ltd, Treventis Corp, UCB SA, Varinel Inc, Virobay Inc, Vitae Pharmaceuticals Inc, VLP Therapeutics LLC, Voyager Therapeutics Inc, vTv Therapeutics Inc, Vybion Inc, Wellstat Therapeutics Corp, Xigen SA, Zhejiang Hisun Pharmaceutical Co Ltd.
The Alzheimer's disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alzheimer's disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 23, 40, 62, 1, 251, 90 and 5 respectively.
Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 109 and 46 molecules, respectively.
Alzheimer's disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The pipeline guide provides a snapshot of the global therapeutic landscape of Alzheimer's disease (Central Nervous System).The pipeline guide reviews pipeline therapeutics for Alzheimer's disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Alzheimer's disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Alzheimer's disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Alzheimer's disease (Central Nervous System).
Access Complete Research Report On Alzheimer's Disease - Therapeutics Development Pipeline at www.reportsnreports.com/purchase.aspx?name=928816
Table of Contents:
- Introduction 12
- Alzheimer's Disease - Overview
- Alzheimer's Disease - Therapeutics Development
- Alzheimer's Disease - Therapeutics Assessment
- Alzheimer's Disease - Companies Involved in Therapeutics Development
- Alzheimer's Disease - Drug Profiles
- Alzheimer's Disease - Dormant Projects
- Alzheimer's Disease - Discontinued Products
- Alzheimer's Disease - Product Development Milestones